Terazosin
- Product NDC
- 66267-389
- 11-digit product format
- 662670389
- Labeler code
- 66267
- Product ID
- 66267-389_1fa6d444-4cb4-0343-e063-6394a90aa95a
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Terazosin Hydrochloride
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- NuCare Pharmaceuticals, Inc.
- Application
- ANDA075317
- Marketing category
- ANDA
- Marketing start
- 2004-12-20
- Substance
- TERAZOSIN HYDROCHLORIDE
- Active strength
- 2 mg/1
- Pharmacologic classes
- Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Terazosin
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| TERAZOSIN HYDROCHLORIDE | 2 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | D32S14F082 |
| Rxcui | 313217 |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 66267-389-90 | Terazosin | 90 in 1 BOTTLE | CAPSULE | 90 | | 4 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 66267-389 | TERAZOSIN (TERAZOSIN HYDROCHLORIDE) CAPSULE [NUCARE PHARMACEUTICALS, INC.] | 4 | Current NDC, Legacy NDC, 1 package rows | 20240815_40e5ae44-708a-15a3-e054-00144ff8d46c.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 66267-389-90 | 66267038990 | 90 CAPSULE in 1 BOTTLE (66267-389-90) | 90 capsule | 2016-11-09 | 0000-00-00 | No | No | Current |